Home › Amblyopia › Massachusetts › Boston
Amblyopia clinical trials in Boston, MA
4 studies for Amblyopia are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RecruitingPhase 3
- New England College of Optometry, Boston
- Boston Medical Center, Boston
- Boston Children's Hospital Waltham, Boston
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RecruitingPhase 3
- New England College of Optometry, Boston
- Boston Medical Center, Boston
- Boston Children's Hospital Waltham, Boston
Valproate for the Treatment of Residual Amblyopia
RecruitingPhase 1/2
- Boston Children's Hospital, Boston
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RecruitingPhase 3
- Boston Medical Center, Boston
- Boston Children's Hospital Waltham, Boston
About Amblyopia
Learn about amblyopia, or "lazy eye," the most common cause of visual problems in children. It happens when an eye fails to work properly with the brain.
More about Amblyopia on MedlinePlus
Amblyopia trials in other cities
- Baltimore, MD4 studies
- Naperville, IL4 studies
- Dallas, TX4 studies
- Philadelphia, PA4 studies
- New York City, NY4 studies
- Chicago, IL4 studies
- Erie, PA3 studies
- Sacramento, CA3 studies
- Cincinnati, OH3 studies
- Mountain View, CA3 studies
- Irvine, CA3 studies
- Durham, NC3 studies
Other studies in Boston
- Breast Cancer110 studies
- Cancer (all types)90 studies
- Non-Small Cell Lung Cancer87 studies
- Lung Cancer63 studies
- Colorectal Cancer62 studies
- Ovarian Cancer62 studies
- Metastatic Cancer61 studies
- Prostate Cancer56 studies
- Endometrial Cancer51 studies
- Depression50 studies
- Heart Failure46 studies
- Multiple Myeloma45 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.